Last reviewed · How we verify
MV140
MV140 is a polyvalent bacterial lysate vaccine that stimulates innate and adaptive immune responses to prevent recurrent urinary tract infections.
MV140 is a polyvalent bacterial lysate vaccine that stimulates innate and adaptive immune responses to prevent recurrent urinary tract infections. Used for Prevention of recurrent urinary tract infections in adults.
At a glance
| Generic name | MV140 |
|---|---|
| Sponsor | Inmunotek S.L. |
| Drug class | Bacterial lysate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MV140 contains inactivated lysates from four uropathogenic bacteria (Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, and Morganella morganii) commonly responsible for recurrent UTIs. The vaccine is administered orally and intramuscularly to activate mucosal and systemic immunity, enhancing the body's ability to recognize and eliminate these pathogens before infection establishes.
Approved indications
- Prevention of recurrent urinary tract infections in adults
Common side effects
- Local injection site reactions
- Gastrointestinal symptoms
- Fever
- Fatigue
Key clinical trials
- MV-140 Efficacy in Recurrent Urinary Tract Infections in a Cohort of Portuguese Adult Patients
- Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)
- Evaluation of the Efficacy and Safety of MV140 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MV140 CI brief — competitive landscape report
- MV140 updates RSS · CI watch RSS
- Inmunotek S.L. portfolio CI